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FPIN's Clinical Inquiries 
What Is the Best Antiviral Agent for Influenza Infection? 
Searchable Question 
What is the best antiviral treatment for influenza? 
Evidence-Based Answer 
Four antiviral agents have been approved by the U.S. Food and Drug Administration for the 
treatment of influenza infection: amantadine (Symmetrel), oseltamivir (Tamiflu), rimantadine 
(Flumadine), and zanamivir (Relenza). No head-to-head trials have compared the effectiveness 
of these agents, and no direct evidence exists regarding their relative efficacy. In the absence of 
specific contraindications, amantadine and rimantadine are preferred for use in most patients 
because these two agents cost less than the other two. Patients with renal insufficiency or a 
seizure disorder should not take amantadine, and patients with chronic obstructive pulmonary 
disease or asthma should not take zanamivir. [Strength of recommendation: C] 
Evidence Summary 
The efficacy of each agent has been studied individually. Two systematic reviews showed that 
amantadine and rimantadine reduced the duration of influenza A symptoms by about one day 
compared with placebo when the agents were given within 48 hours of symptom onset.1 
Three systematic reviews found that zanamivir reduced the duration of influenza A and influenza 
B symptoms by about one day compared with placebo when it was given within 48 hours of 
symptom onset.2,3,4 Three systematic reviews also showed that oseltamivir was effective in 
reducing the duration of symptoms of influenza A and influenza B by one day compared with 
placebo. However, unlike the other agents, oseltamivir must be given within 36 hours of 
symptom onset.2,3,5 
There is insufficient evidence regarding the effects of antiviral agents in reducing serious 
complications of influenza. One systematic review showed that oseltamivir reduced the 
incidence of otitis media following influenza in children.3 
Adverse effects of antiviral agents were addressed in a nonsystematic review by the Centers for 
Disease Control and Prevention (CDC) in their annual report on influenza.6 The CDC noted that 
in a six-week study of healthy adults taking amantadine, rimantadine, or placebo, the incidence 
of central nervous system (CNS) side effects such as anxiety, insomnia, and difficulty 
concentrating was 4 percent in the placebo group, 6 percent in the rimantadine group (at 200 mg 
daily), and 13 percent in the amantadine group (at 200 mg daily). The CDC noted other studies 
that found more serious adverse effects such as delirium and seizures, but these adverse effects 
have occurred primarily in older patients taking amantadine for longer periods, and in patients 
with renal insufficiency or a comorbid seizure disorder. 
The neuraminidase inhibitors (i.e., oseltamivir, zanamivir) are not thought to cause CNS side 
effects. In one review2 comparing neuraminidase inhibitors with placebo, patients taking the 
inhibitors had an incidence of gastrointestinal symptoms of 12.7 percent compared with 4.9 
percent in the placebo group (odds ratio [OR], 2.57; 95 percent confidence interval [CI], 1.19 to 
5.52). The incidence of overall adverse effects in patients taking neuraminidase inhibitors was 
37.6 percent versus 18 percent in the placebo group (OR, 2.59; 95 percent CI, 1.59 to 4.21).2 
Asthma is a contraindication to the use of zanamivir because the latter may induce 
bronchospasms.6 
Amantadine and rimantadine treat only influenza type A infection. However, the vast majority of 
influenza in the United States is type A. During the 2003-2004 influenza season, 99.4 percent of 
the reported cases were type A.7 The accompanying table compares the four antiviral agents. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Antiviral Agents for Treatment of Influenza Infection 
 
Agent 
Age 
approved 
for 
treatment 
Mechanism of 
action 
Approximate 
cost* 
Influenza 
viruses 
inhibited Usual dosage 
Route of 
administration Side effects 
Amantadine 
(Symmetrel)  
Adults 
and 
children 
> one 
year 
Blocks activity 
of viral M2 
protein 
$14 for five-
day course 
(capsule) 
A 100 mg twice 
daily for three 
to five days 
(reduced 
dosage in 
elderly 
patients, 
those with 
hepatic/renal 
impairment, 
and in 
children one 
to nine years 
of age) 
Oral (capsule 
and syrup) 
CNS and GI 
symptoms 
(dose 
dependent) 
Oseltamivir 
(Tamiflu)  
Adults 
and 
children 
> one 
year 
Neuraminidase 
inhibitor 
$67 for five-
day course 
(capsule) 
A, B 75 mg twice 
daily for five 
days (reduced 
dosage in 
patients with 
hepatic/renal 
impairment 
and in 
children one 
to 13 years of 
age) 
Oral (capsule 
and powder for 
oral 
suspension) 
GI symptoms 
Rimantadine 
(Flumadine)  
Adults 
and 
children 
> one 
year 
Blocks activity 
of viral M2 
protein 
$22 for five-
day course 
(tablet) 
A 100 mg twice 
daily for five 
to seven days 
(reduced 
dosage in 
elderly 
patients, 
those with 
hepatic/renal 
impairment, 
and in 
children one 
to 10 years of 
age) 
Oral (tablet 
and syrup) 
CNS and GI 
symptoms 
Zanamivir 
(Relenza)  
Adults 
and 
children 
> seven 
years  
Neuraminidase 
inhibitor  
$57 for one 
inhaler, five-
day course  
A, B  Two 
inhalations 
(one 5-mg 
blister per 
inhalation for 
a total dose of 
10 mg) twice 
daily for five 
days  
Oral inhalation 
(blisters of 
powder for 
inhalation 
using the 
Diskhaler 
device) 
Bronchospasm 
in patients 
with COPD or 
asthma  
 
 
CNS = central nervous system; GI = gastrointestinal; COPD = chronic obstructive pulmonary disease. 
*-Average wholesale cost, based on Red Book, Montvale, N.J.: Medical Economics Data, 2004. 
 
 
Recommendations from Others 
The CDC Advisory Committee on Immunization Practices (ACIP) recommends administration 
of one of the four antiviral agents within two days of influenza symptom onset. If given within 
this time period, these agents can reduce the duration of uncomplicated influenza in otherwise 
healthy adults. None of the four agents has been demonstrated to be effective in preventing 
serious influenza-related complications. The ACIP warns that the use of antiviral agents should 
not be considered a substitute for influenza vaccination.6 
Clinical Commentary 
Because the four antiviral agents have similar efficacy, the family physician should consider 
cost, side effect profiles, spectrum of coverage, and patient's age when selecting an agent. 
Amantadine and rimantadine are less expensive and have a side effect profile similar to that of 
placebo. However, the use of amantadine should be avoided in patients 65 years and older, and 
in patients with renal insufficiency or a seizure disorder. Patients with asthma should not receive 
zanamivir. Although amantadine and rimantadine are limited in their spectrum of coverage, this 
is a relatively minor issue. Influenza type B is a mild illness and is not associated with epidemic 
outbreaks in the United States. 
HEATHER BITTNER FAGAN, M.D. 
AMY HOLLIHAN MOELLER, D.O.  
Christiana Care Health System, Family Medicine Residency Program Wilmington, Delaware 
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